Interview: Ex-Astellas Boss Takenaka Urges Mid-Size Makers to Be More Open to Academia in Pathological Research

As Japanese drug makers see it increasingly difficult to count on their off-patent brands, mid-sized players are readopting the business model of making profits while their drugs are on patent. Many firms seem to be in-licensing drug candidates as a...read more